Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer

Overview

Paraneoplastic cochleovestibulopathy (PCVP) is a rare neurological syndrome characterized by sudden or rapidly progressive sensorineural hearing loss and vestibular dysfunction associated with malignancies, including breast cancer. This report presents two Chinese patients with PCVP linked to breast adenocarcinoma, highlighting diagnostic challenges and treatment outcomes.

Background

PCVP was first described in 2014 as an atypical paraneoplastic neurological syndrome involving cochlear and vestibular dysfunction unresponsive to steroid therapy. It is often associated with malignancies such as breast adenocarcinoma, small-cell lung cancer, thymoma, and lymphoma. Due to its rarity and atypical presentation, PCVP is frequently misdiagnosed and inadequately treated. Understanding its clinical features is essential for early diagnosis and management.

Data Highlights

Two cases of PCVP associated with breast cancer were described: both patients presented with bilateral sensorineural hearing loss and vertigo unresponsive to steroids and immunotherapy. Imaging studies showed no structural abnormalities. Breast cancer diagnosis was confirmed by histopathology and immunohistochemistry. Treatment included endocrine therapy and surgical excision of breast tumors. Hearing loss persisted despite cancer treatment, while vertigo showed some improvement.

Key Findings

• PCVP presents with sudden or rapidly progressive bilateral sensorineural hearing loss and vestibular symptoms such as vertigo and ataxia.
• Standard steroid therapy and immunoglobulin treatment often fail to improve hearing loss in PCVP patients.
• PCVP can be associated with breast adenocarcinoma, confirmed by imaging and histopathology.
• Autoantibodies against neuronal antigens may be detected, though specific paraneoplastic antibodies can be absent.
• Vertigo symptoms may improve after cancer treatment, but hearing loss frequently persists, sometimes requiring cochlear implantation or hearing aids.
• Early recognition of PCVP is critical to prompt cancer diagnosis and appropriate management.

Clinical Implications

Clinicians should consider PCVP in patients presenting with unexplained bilateral sensorineural hearing loss and vestibular dysfunction, especially when unresponsive to steroids. Comprehensive evaluation for underlying malignancies, particularly breast cancer, is warranted. Early diagnosis may facilitate timely cancer treatment, potentially improving vestibular symptoms, although hearing loss may remain irreversible.

Conclusion

PCVP is a rare paraneoplastic syndrome linked to breast cancer that manifests as progressive cochleovestibular dysfunction resistant to conventional therapies. Awareness of this entity can aid in early cancer detection and guide multidisciplinary management to improve patient outcomes.

References

1. Greene 2014 -- Paraneoplastic Cochleovestibulopathy Description
2. Breast Adenocarcinoma Association Case Report
3. Small-Cell Lung Cancer and PCVP
4. Thymoma and PCVP Case Report
5. Lymphoma and PCVP Case Report